💨 Abstract

The FDA is introducing a new initiative to expedite reviews for selected medicines that benefit American health. This program, announced by Commissioner Marty Makary, aims to review certain drugs in just one to two months, much faster than the current six to ten months. The agency will issue "national priority vouchers" to companies aligned with U.S. priorities, granting them extra FDA support and streamlined reviews.

Courtesy: WTOP Staff